Tata 1mg reported robust FY26 results, underscoring improving unit economics and a clear path toward profitability. Consolidated revenue rose 23% year-on-year to ₹2,936 crore, while net loss narrowed to ₹287 crore, reflecting tighter cost controls and scale benefits across its e-pharmacy, diagnostics, and specialty care businesses.
Revenue momentum and operating discipline
The core healthcare business posted a turnover of ₹2,439.8 crore in FY26 alongside a reduction in losses. Management indicated that by December 2025, all core verticals—excluding the brick-and-mortar rollout—had turned EBITDA positive, with positive momentum sustained through the March quarter.
Diagnostics expanded 40%, crossing ₹600 crore in annual recurring revenue, supported by networked labs and home sample collection. The specialty pharma portfolio—covering oncology, vaccines, and obesity care—grew 65%, helped by higher adherence programmes and clinical support. The company’s direct-to-consumer healthcare products business surpassed ₹200 crore in ARR while remaining profitable.
Market share gains in e-pharmacy
Tata 1mg now leads India’s e-pharmacy segment by gross merchandise value, with an estimated 31% market share. The shift follows softer marketing spends among peers and a sector-wide pivot to sustainable growth. Industry watchers note that scale, fulfilment reliability, and medical content quality have become key differentiators in digital health commerce.
Omnichannel footprint and faster fulfilment
The company is accelerating its offline presence to complement online demand. It aims to operate about 500 stores by end-2026, rising to 600–700 by FY27. Stores are designed to serve urgent or immediate-need purchases, while chronic and subscription medicines continue to be fulfilled digitally.
Each outlet carries roughly 3,000–5,000 SKUs, compared with nearly eight lakh products available online. The expanded retail network is also being used as micro-fulfilment nodes, enabling 30–60 minute deliveries in major cities without compromising prescription checks or cold-chain integrity.
Enterprise healthcare gains traction
The business-to-business segment contributed around 30% of total revenue in FY26, doubling year-on-year. A recent tie-up with OneBanc integrates medicines, diagnostics, and preventive health services into an AI-enabled salary platform, broadening employer-led health benefits and cashless access for employees.
Funding discussions and path to listing
Tata 1mg is in advanced talks to raise around $200 million, though current capital needs are estimated at $125 million. Valuation remains the key sticking point, with Tata Digital—holding roughly 63%—seeking about $1.25 billion, while prospective investors are understood to be in the $750–800 million range. Governance terms and board representation are also under negotiation. In the event external funding does not close, Tata Sons may infuse approximately $75 million.
On listing plans, CEO Prashant Tandon has reiterated that the company will consider an IPO only after achieving full profitability, including investments in new stores. The stated target is the fourth quarter of FY27.
Quality and compliance infrastructure
Tata 1mg operates 19 NABL-accredited laboratories across 70 cities, anchored by a CAP-accredited National Reference Laboratory. The company maintains multi-layer quality controls, including technician credentialing, proficiency testing, and a clinical content governance framework overseen by specialist doctors and medical editors.
With higher revenue, lower cash burn, and expanding services across diagnostics, specialty pharma, and enterprise health, Tata 1mg is consolidating its position in India’s digital healthcare ecosystem while preparing for the next phase of growth.
